Citation: L. Agren et al., A GENETICALLY-ENGINEERED NONTOXIC VACCINE ADJUVANT THAT COMBINES B-CELL TARGETING WITH IMMUNOMODULATION BY CHOLERA-TOXIN A1 SUBUNIT, The FASEB journal, 12(5), 1998, pp. 5264-5264
Citation: L. Agren et al., A NOVEL CONCEPT IN MUCOSAL ADJUVANTICITY - THE CTA1-DD ADJUVANT IS A B-CELL-TARGETED FUSION PROTEIN THAT INCORPORATES THE ENZYMATICALLY ACTIVE CHOLERA-TOXIN A1 SUBUNIT, Immunology and cell biology, 76(3), 1998, pp. 280-287
Citation: C. Svanholm et al., AMPLIFICATION OF T-CELL AND ANTIBODY-RESPONSES IN DNA-BASED IMMUNIZATION WITH HIV-1 NEF BY COINJECTION WITH A GM-CSF EXPRESSION VECTOR, Scandinavian journal of immunology, 46(3), 1997, pp. 298-303
Authors:
KJERRULF M
LOWENADLER B
SVANHOLM C
LYCKE N
Citation: M. Kjerrulf et al., TANDEM REPEATS OF T-HELPER EPITOPES ENHANCE IMMUNOGENICITY OF FUSION PROTEINS BY PROMOTING PROCESSING AND PRESENTATION, Molecular immunology, 34(8-9), 1997, pp. 599-608
Citation: Lc. Agren et al., GENETICALLY-ENGINEERED NONTOXIC VACCINE ADJUVANT THAT COMBINES B-CELLTARGETING WITH IMMUNOMODULATION BY CHOLERA-TOXIN A1 SUBUNIT, The Journal of immunology, 158(8), 1997, pp. 3936-3946
Citation: N. Lycke et al., A NOVEL B-CELL TARGETED GENE FUSION PROTEIN-ENCODING THE CHOLERA-TOXIN A1 SUBUNIT ACTS AS A POTENT VACCINE ADJUVANT, The FASEB journal, 10(6), 1996, pp. 492-492
Citation: M. Kierrulf et al., OPTIMAL ESCHERICHIA-COLI ST-FUSION PROTEIN DESIGN FOR EFFICIENT ANTIGEN PROCESSING AND PRESENTATION GREATLY POTENTIATES HOST IMMUNE-RESPONSES, The Journal of immunology, 150(8), 1993, pp. 229-229